CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
STEMPhage is developing a macrophage-based therapy for solid tumors, leveraging engineered macrophages that can effectively infiltrate and attack tumors. This innovative approach aims to provide a scalable, off-the-shelf treatment option for cancer patients.
The STEMPhage project at TU Dresden aims to develop a pioneering macrophage-based therapy for the treatment of solid tumors.
Solid tumors account for 90% of all cancers and remain largely inaccessible to current cell therapies, as T cells, for example, often fail to effectively infiltrate them.
Macrophages, by contrast, are innate immune cells that are naturally recruited into tumors, where they can not only destroy tumor cells directly but also activate other immune cells to mount a coordinated…
TECHNISCHE UNIVERSITAET DRESDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
